Pharsight

1. Luvox Cr patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7465462	JAZZ PHARMS	Multiparticulate controlled release selective serotonin reuptake inhibitor formulations	May, 2020 (4 years ago)

Drugs and Companies using FLUVOXAMINE MALEATE ingredient

Market Authorisation Date: 28 February, 2008

Treatment: Treatment of obsessive compulsive disorder treatable with an ssri

Dosage: CAPSULE, EXTENDED RELEASE

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mg	20 Apr, 2009	1	13 Mar, 2013	10 May, 2020	Extinguished
150 mg	13 Apr, 2009	1	13 Mar, 2013	10 May, 2020	Non-Forfeiture

Strength	Dosage	Availability
100MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE	Discontinued
150MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE	Discontinued

LUVOX CR family patents

2. Xyrem patent expiration

Application	Filing Date	Opposition Party	Legal Status

EP17200764A	2020-09-11	Ter Meer Steinmeister & Partner Patentanwälte mbB	Granted and Under Opposition
EP17200764A	2020-09-10	Hexal AG	Granted and Under Opposition
EP17200764A	2020-09-02	Zentiva, k.s.	Granted and Under Opposition
EP17200764A	2020-03-16	Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB	Granted and Under Opposition
EP14709858A	2018-08-14	Hexal AG	Revoked
EP14709858A	2018-08-14	Ter Meer Steinmeister & Partner Patentanwälte mbB	Revoked
EP14709858A	2018-07-23	Hoffmann Eitle	Revoked

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8731963	September, 2015	Final Written Decision	Jazz Pharmaceuticals, Inc.	Par Pharmaceutical, Inc. et al.
US7765106	August, 2015	Final Written Decision	Jazz Pharmaceuticals, Inc.	Wockhardt Bio AG et al.
US8772306	February, 2016	Terminated-Denied	Jazz Pharmaceutical, Inc.	Amneal Pharmaceuticals LLC
US7668730	January, 2015	Final Written Decision	Jazz Pharmaceuticals, Inc.	PAR PHARMACEUTICAL, INC. et al.
US7668730	August, 2015	Final Written Decision	Jazz Pharmaceuticals, Inc.	Wockhardt Bio AG et al.
US7765106	January, 2015	Final Written Decision	Jazz Pharmaceuticals, Inc.	Amneal Pharmaceuticals LLC et al.
US7765107	January, 2015	Final Written Decision	Jazz Pharmaceuticals, Inc.	Amneal Pharmaceuticals LLC et al.
US7765107	August, 2015	Final Written Decision	Jazz Pharmaceuticals, Inc.	Wockhardt Bio AG et al.
US7895059	January, 2015	Final Written Decision	Jazz Pharmaceuticals, Inc.	PAR PHARMACEUTICAL, INC.
US7895059	August, 2015	FWD Entered	Jazz Pharmaceuticals, Inc.	Amneal Pharmaceuticals LLC
US7895059	August, 2015	FWD Entered	Jazz Pharmaceuticals, Inc.	Wockhardt Bio AG
US8457988	January, 2015	Final Written Decision	Jazz Pharmaceuticals, Inc.	PAR PHARMACEUTICAL, INC.
US8457988	August, 2015	FWD Entered	Jazz Pharmaceuticals, Inc.	Amneal Pharmaceuticals LLC
US8457988	August, 2015	FWD Entered	Jazz Pharmaceuticals, Inc.	Wockhardt Bio AG
US8589182	January, 2015	FWD Entered	Jazz Pharmaceuticals, Inc.	Amneal Pharmaceuticals LLC
US8589182	August, 2015	Final Written Decision	Jazz Pharmaceuticals, Inc.	Wockhardt Bio AG et al.
US8772306	October, 2015	Terminated-Settled	Jazz Pharmaceutical, Inc.	Ranbaxy, Inc.
US9050302	March, 2016	Terminated-Denied	Jazz Pharmaceuticals Ireland Limited	RANBAXY INC
US8772306	October, 2015	Terminated-Denied	Jazz Pharmaceutical, Inc.	Par Pharmaceutical, Inc.
US7895059	April, 2015	Terminated-Denied	Jazz Pharmaceuticals, Inc.	Coalition for Affordable Drugs III LLC
US7765106	August, 2014	Terminated-Denied	Jazz Pharmaceuticals, Inc.	Roxane Laboratories, Inc.
US7765107	August, 2014	Terminated-Denied	Jazz Pharmaceuticals Inc.	Roxane Laboratories, Inc.
US7668730	July, 2014	Terminated-Denied	Jazz Pharmaceuticals, Inc.	PAR PHARMACEUTICAL, INC.
US7895059	June, 2014	Terminated-Denied	Jazz Pharmaceuticals, Inc.	Amneal Pharmaceuticals, LLC
US8457988	July, 2014	Terminated-Denied	Jazz Pharmaceuticals, Inc.	Amneal Pharmaceuticals, LLC
US8589182	July, 2014	Terminated-Denied	Jazz Pharmaceuticals, Inc.	PAR PHARMACEUTICAL, INC.
US7668730	May, 2008	Decision	Dayton T. Reardan et al

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324275	JAZZ PHARMS	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	Dec, 2019 (4 years ago)
US7851506	JAZZ PHARMS	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	Dec, 2019 (4 years ago)
US8263650	JAZZ PHARMS	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	Dec, 2019 (4 years ago)
US9539330	JAZZ PHARMS	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	Dec, 2019 (4 years ago)
US8952062	JAZZ PHARMS	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	Dec, 2019 (4 years ago)
US8859619	JAZZ PHARMS	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	Dec, 2019 (4 years ago)
US8324275 (Pediatric)	JAZZ PHARMS	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	Jun, 2020 (4 years ago)
US8952062 (Pediatric)	JAZZ PHARMS	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	Jun, 2020 (4 years ago)
US8859619 (Pediatric)	JAZZ PHARMS	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	Jun, 2020 (4 years ago)
US9539330 (Pediatric)	JAZZ PHARMS	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	Jun, 2020 (4 years ago)
US8263650 (Pediatric)	JAZZ PHARMS	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	Jun, 2020 (4 years ago)
US7851506 (Pediatric)	JAZZ PHARMS	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	Jun, 2020 (4 years ago)
US7262219	JAZZ PHARMS	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	Jul, 2020 (4 years ago)
US6780889	JAZZ PHARMS	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	Jul, 2020 (4 years ago)
US6780889 (Pediatric)	JAZZ PHARMS	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	Jan, 2021 (3 years ago)
US7262219 (Pediatric)	JAZZ PHARMS	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	Jan, 2021 (3 years ago)
US7895059	JAZZ PHARMS	Sensitive drug distribution system and method	Dec, 2022 (1 year, 8 months ago)
US8731963	JAZZ PHARMS	Sensitive drug distribution system and method	Dec, 2022 (1 year, 8 months ago)
US8589182	JAZZ PHARMS	Sensitive drug distribution system and method	Dec, 2022 (1 year, 8 months ago)
US8457988	JAZZ PHARMS	Sensitive drug distribution system and method	Dec, 2022 (1 year, 8 months ago)
US7895059 (Pediatric)	JAZZ PHARMS	Sensitive drug distribution system and method	Jun, 2023 (1 year, 2 months ago)
US8731963 (Pediatric)	JAZZ PHARMS	Sensitive drug distribution system and method	Jun, 2023 (1 year, 2 months ago)
US8457988 (Pediatric)	JAZZ PHARMS	Sensitive drug distribution system and method	Jun, 2023 (1 year, 2 months ago)
US8589182 (Pediatric)	JAZZ PHARMS	Sensitive drug distribution system and method	Jun, 2023 (1 year, 2 months ago)
US7668730	JAZZ PHARMS	Sensitive drug distribution system and method	Jun, 2024 (2 months ago)
US7765107	JAZZ PHARMS	Sensitive drug distribution system and method	Jun, 2024 (2 months ago)
US7765106	JAZZ PHARMS	Sensitive drug distribution system and method	Jun, 2024 (2 months ago)
US7765107 (Pediatric)	JAZZ PHARMS	Sensitive drug distribution system and method	Dec, 2024 (3 months from now)
US7668730 (Pediatric)	JAZZ PHARMS	Sensitive drug distribution system and method	Dec, 2024 (3 months from now)
US7765106 (Pediatric)	JAZZ PHARMS	Sensitive drug distribution system and method	Dec, 2024 (3 months from now)
US11253494	JAZZ PHARMS	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Mar, 2033 (8 years from now)
US8772306	JAZZ PHARMS	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Mar, 2033 (8 years from now)
US9050302	JAZZ PHARMS	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Mar, 2033 (8 years from now)
US10864181	JAZZ PHARMS	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Mar, 2033 (8 years from now)
US11986446	JAZZ PHARMS	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Mar, 2033 (8 years from now)
US9486426	JAZZ PHARMS	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Mar, 2033 (8 years from now)
US10213400	JAZZ PHARMS	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Mar, 2033 (8 years from now)
US8772306 (Pediatric)	JAZZ PHARMS	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Sep, 2033 (9 years from now)
US9486426 (Pediatric)	JAZZ PHARMS	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Sep, 2033 (9 years from now)
US9050302 (Pediatric)	JAZZ PHARMS	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Sep, 2033 (9 years from now)
US11253494 (Pediatric)	JAZZ PHARMS	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Sep, 2033 (9 years from now)
US10213400 (Pediatric)	JAZZ PHARMS	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Sep, 2033 (9 years from now)
US10864181 (Pediatric)	JAZZ PHARMS	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Sep, 2033 (9 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE)	Nov 18, 2012
New Patient Population(NPP)	Oct 26, 2021
Orphan Drug Exclusivity(ODE-231)	Oct 26, 2025
Pediatric Exclusivity(PED)	Apr 26, 2026

Drugs and Companies using SODIUM OXYBATE ingredient

Market Authorisation Date: 17 July, 2002

Treatment: Method of treating excessive daytime sleepiness in patients with narcolepsy; Method of treating cataplexy in patients with narcolepsy; Method of treating a patient with a prescription drug using a com...

Dosage: SOLUTION

Pharsight

Pharsight

Jazz Pharms patent expiration

1. Luvox Cr patent expiration

LUVOX CR family patents

2. Xyrem patent expiration

XYREM family patents

Have Questions?

Pharsight

Pharsight

Jazz Pharms patent expiration

1. Luvox Cr patent expiration

LUVOX CR family patents

2. Xyrem patent expiration

XYREM family patents

Related content

Have Questions?